Oxford BioTherapeutics To Collaborate With Seattle Genetics On ADCs
This article was originally published in The Pink Sheet Daily
In tandem with Seattle Genetics, Oxford BioTherapeutics hopes to take a monoclonal antibody product for cancer into the clinic next year.
You may also be interested in...
FDA approves the antibody-drug conjugate for late stage Hodgkins lymphoma and systemic anaplastic large cell lymphoma Aug. 19.
Alliance is first OBT partnership with a big pharma; deal grants biotech double-digit royalties on products it develops through proof of concept.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.